efficacy and safety of various aspirin doses in patients with ST-segment myocardial infarction undergoing primary percutaneous coronary intervention

comparison of efficacy and safety of high-dose versus low-dose aspirin in patients with ST-segment myocardial infarction (STEMI) after primary percutaneous coronary intervention

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014122220392N1

Enrollment

175

Registered

2016-02-28

Start date

2013-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-segment elevation myocardial infarction (STEMI). Acute myocardial infarction

Interventions

Intervention 1: The intervention group receive aspirin with chemical substance of acetyl salisilic acid as 325 mg orally tablet once a day for a duration of 1 month from days 2-30 after primary PCI.

Treatment - Drugs

The intervention group receive aspirin with chemical substance of acetyl salisilic acid as 325 mg orally tablet once a day for a duration of 1 month from days 2-30 after primary PCI.

The control group receive aspirin with chemical substance of acetyl salisilic acid as 80 mg orally tablet once a day for a duration of 1 month from days 2-30 after primary PCI.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with ST-segment myocardial infarction who underwent primary PCI within 12 hours of the onset of heart attack. Exclusion Criteria:patients with a history of gastrointestinal bleeding and hemorrhagic stroke; opium and alcohol abusers, patients with coagulopathies or history of anticoagulant therapy ; major surgery within 6 weeks; platelets less than 100,000/ microliter; hematocrit less than 25%; creatinine more than 4 mg/dl

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Major adverse cardiovascular outcome. Timepoint: one month and one year after the study. Method of measurement: telephone interview and echcardiogarphy for patients with primary outcome.	—

Secondary

Measure	Time frame
Major bleeding. Timepoint: one month and one year after primary PCI. Method of measurement: telephone interview.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohaddese Pursadeghi

Guilan university of medical sciences

saman.khojasteh@yahoo.com+98 13 3361 8177

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026